oxonic acid has been researched along with Mucositis, Oral in 19 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence of oral mucositis was significantly lower in the treatment group (9." | 2.90 | A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer. ( Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, M; Toyomasu, Y; Yanai, M; Yanoma, T, 2019) |
| "Previous studies have shown sex-related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown." | 2.90 | Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. ( Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Koizumi, W; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2019) |
| "Gemcitabine was administered at an escalating dose of 600, 800 and 1,000 mg/m(2) over 30 min on day 1, and oral S-1 at a dose of 40 mg/m(2) twice daily and oral leucovorin at a dose of 25 mg twice daily on days 1-7, every 2 weeks." | 2.79 | A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N, 2014) |
| "We developed a combination chemotherapy, comprising weekly dosing of iv cisplatin (days 1 and 8) combined with a fixed dose (70 mg/m2/day) of S-1 (days 1-14) for patients with metastatic gastric cancer." | 2.72 | [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer]. ( Hyodo, I, 2006) |
| "Our analysis suggests that cancer of the oropharynx and CRT are important risk factors for severe OM in HNC patients that undergo RT or CRT involving S-1." | 1.46 | Analysis of the Risk Factors for Severe Oral Mucositis in Head and Neck Cancer after Chemoradiotherapy with S-1. ( Fujii, N; Hashimoto, T; Kogo, M; Nagatani, A; Naito, Y; Ogawa, Y; Okabe, T; Sasaki, T; Sunaga, T; Tomura, K, 2017) |
| "A total of 11 patients with head and neck cancer who received concurrent chemoradiotherapy with S-1 were examined." | 1.40 | [The timing of the appearance of oral mucositis induced by concurrent chemoradiotherapy with S-1 for head and neck cancer]. ( Futagami, K; Nakagawa, T; Nomoto, S; Ogata, K; Takase, H; Tokunaga, S; Yonekita, H; Yoshimitsu, K, 2014) |
| "TS-1 has been used for the treatment of gastric cancer, both in the adjuvant and metastatic setting, and is increasingly being used in other malignancies such as colon, pancreatic and non-small cell lung cancer." | 1.37 | Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer. ( Aw, CW; Lee, SC; Lim, R; Lim, TC; Tan, CS; Yeo, SW, 2011) |
| " We therefore reduced the dosage of TS-1 from 80 mg/body/day to 60 mg/body/day." | 1.34 | [A resected case of advanced gastric cancer after treatment with low-dosage TS-1]. ( Aoyagi, K; Imaizumi, T; Koufuji, K; Matono, K; Miyagi, M; Ogata, Y; Shirouzu, K; Takeda, J; Yano, S, 2007) |
| "In two patients with advanced pancreatic cancer with cervical lymph node or liver metastasis and no indication of pancreatic resection and radiotherapy, oral treatment with S-1 (an anti-cancer agent of fluoropyrimidine derivative) exerted high anti-tumor activity on the metastatic lesions." | 1.33 | [Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy]. ( Funakoshi, A; Senju, T; Sumii, T, 2006) |
| "We treated a recurrent gastric cancer patient with chronic renal failure who developed grade 2 HFS, grade 2 conjunctivitis and grade 3 stomatitis soon after TS-1 administration." | 1.32 | [A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Xu, R | 1 |
| Xu, J | 1 |
| Denda, T | 1 |
| Ikejiri, K | 1 |
| Shen, L | 1 |
| Toh, Y | 1 |
| Shimada, K | 2 |
| Kato, T | 1 |
| Sakai, K | 1 |
| Yamamoto, M | 1 |
| Mishima, H | 1 |
| Wang, J | 1 |
| Baba, H | 1 |
| Toyomasu, Y | 1 |
| Mochiki, E | 1 |
| Yanai, M | 1 |
| Suzuki, M | 1 |
| Yanoma, T | 1 |
| Kimura, A | 1 |
| Kogure, N | 1 |
| Ogata, K | 2 |
| Kuwano, H | 1 |
| Yamada, Y | 1 |
| Koizumi, W | 1 |
| Nishikawa, K | 1 |
| Gotoh, M | 1 |
| Fuse, N | 1 |
| Sugimoto, N | 1 |
| Nishina, T | 1 |
| Amagai, K | 1 |
| Chin, K | 1 |
| Niwa, Y | 1 |
| Tsuji, A | 1 |
| Imamura, H | 1 |
| Tsuda, M | 1 |
| Yasui, H | 2 |
| Fujii, H | 1 |
| Yamaguchi, K | 1 |
| Hironaka, S | 1 |
| Hyodo, I | 2 |
| Nakai, Y | 1 |
| Isayama, H | 1 |
| Saito, K | 1 |
| Sasaki, T | 2 |
| Takahara, N | 1 |
| Hamada, T | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Yamamoto, K | 1 |
| Mohri, D | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Koike, K | 1 |
| Yonekita, H | 1 |
| Takase, H | 1 |
| Futagami, K | 1 |
| Nomoto, S | 1 |
| Yoshimitsu, K | 1 |
| Nakagawa, T | 1 |
| Tokunaga, S | 1 |
| Abdel-Rahman, O | 1 |
| ElHalawani, H | 1 |
| Essam-Eldin, S | 1 |
| Nagatani, A | 1 |
| Ogawa, Y | 1 |
| Sunaga, T | 1 |
| Tomura, K | 1 |
| Naito, Y | 1 |
| Fujii, N | 1 |
| Okabe, T | 1 |
| Hashimoto, T | 1 |
| Kogo, M | 1 |
| Tan, CS | 1 |
| Lim, R | 1 |
| Lim, TC | 1 |
| Aw, CW | 1 |
| Yeo, SW | 1 |
| Lee, SC | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Kimura, Y | 1 |
| Takahashi, K | 1 |
| Yamaguchi, T | 1 |
| Honma, S | 1 |
| Takahashi, T | 1 |
| Hino, S | 1 |
| Shintani, S | 1 |
| Nonaka, T | 1 |
| Hara, S | 1 |
| Hamakawa, H | 1 |
| Shitara, K | 1 |
| Sakata, Y | 1 |
| Kudou, T | 1 |
| Munakata, M | 1 |
| Takahashi, I | 1 |
| Oki, E | 1 |
| Egashira, A | 1 |
| Morita, M | 1 |
| Kakeji, Y | 1 |
| Maehara, Y | 1 |
| Tsuji, H | 1 |
| Nagata, M | 1 |
| Inoue, T | 1 |
| Minami, T | 1 |
| Iwai, H | 1 |
| Ohnishi, S | 1 |
| Yukawa, H | 1 |
| Ogura, M | 1 |
| Yamashita, T | 1 |
| Nagata, K | 1 |
| Sato, M | 1 |
| Harada, K | 1 |
| Saeki, T | 1 |
| Funakoshi, A | 1 |
| Senju, T | 1 |
| Sumii, T | 1 |
| Matono, K | 1 |
| Ogata, Y | 1 |
| Koufuji, K | 1 |
| Aoyagi, K | 1 |
| Yano, S | 1 |
| Miyagi, M | 1 |
| Imaizumi, T | 1 |
| Takeda, J | 1 |
| Shirouzu, K | 1 |
| Inuyama, Y | 1 |
| Kida, A | 1 |
| Tsukuda, M | 1 |
| Kohno, N | 1 |
| Satake, B | 1 |
4 reviews available for oxonic acid and Mucositis, Oral
| Article | Year |
|---|---|
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I | 2016 |
[S-1 for gastric cancer-S-1 monotherapy and its progress].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
[Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
Topics: Animals; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic | 2006 |
[Clinical benefit of S-1 in metastatic breast cancer].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, | 2006 |
8 trials available for oxonic acid and Mucositis, Oral
| Article | Year |
|---|---|
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col | 2017 |
A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Control Studie | 2019 |
Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Respons | 2019 |
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Dose-Respon | 2014 |
[S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2006 |
[Clinical phase I trial of concurrent chemo-radiotherapy with S-1 for T2NO glottic carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deglutit | 2006 |
[Phase I study of concurrent radiotherapy with S-1 for oral squamous cell carcinoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; D | 2006 |
[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Ce | 1998 |
7 other studies available for oxonic acid and Mucositis, Oral
| Article | Year |
|---|---|
[The timing of the appearance of oral mucositis induced by concurrent chemoradiotherapy with S-1 for head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Female; | 2014 |
Analysis of the Risk Factors for Severe Oral Mucositis in Head and Neck Cancer after Chemoradiotherapy with S-1.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Female; | 2017 |
Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diagnosis, Differential; Drug Combinations; | 2011 |
[A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Conjunctivitis; Drug Combinations; Foot Derma | 2003 |
[A case of advanced maxillary carcinoma with cervical lymph node metastases showing a complete response to the combination therapy of CDDP, TS-1 and radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2004 |
[Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Anemia; Antimetabolites, Antineoplastic; Drug Administra | 2006 |
[A resected case of advanced gastric cancer after treatment with low-dosage TS-1].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; D | 2007 |